Related Experiment Videos
Endothelin receptor antagonists: a brief review
1Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA.
Canadian Journal of Physiology and Pharmacology
|November 1, 1994
Summary
Endothelins are potent vasoconstrictors linked to various diseases. Researchers are developing endothelin receptor antagonists to target these conditions, focusing on their binding and vascular effects.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Medicine
Background:
- Endothelins are potent vasoconstrictors implicated in diseases involving hypoxia, ischemia, and vasoconstriction.
- Elevated circulating endothelin levels are observed in numerous pathological conditions compared to healthy subjects.
Purpose of the Study:
- To review novel peptide and nonpeptide endothelin receptor antagonists.
- To analyze the binding potency and vascular activity of these antagonists.
Main Methods:
- Literature review of studies on endothelin receptor antagonists.
- Analysis of binding affinity data.
- Evaluation of in vitro and in vivo vascular activity.
Main Results:
- Identification of various peptide and nonpeptide endothelin receptor antagonists.
- Characterization of their differential binding potencies.
- Assessment of their vascular effects, including vasoconstriction and vasodilation modulation.
Conclusions:
- Endothelin receptor antagonists represent a promising therapeutic strategy for diseases associated with endothelin dysregulation.
- Further research into these antagonists' efficacy and safety is warranted.